Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cilengitide for Subjects With Newly Diagnosed Glioblastoma and Methylated MGMT Gene Promoter - A Multicenter, Open-label, Controlled Phase III Study, Testing Cilengitide in Combination With Standard Treatment (Temozolomide With Concomitant Radiation Therapy, Followed by Temozolomide Maintenance Therapy) Versus Standard Treatment Alone (CENTRIC)

Next Previous
Search
Trial Profile

Cilengitide for Subjects With Newly Diagnosed Glioblastoma and Methylated MGMT Gene Promoter - A Multicenter, Open-label, Controlled Phase III Study, Testing Cilengitide in Combination With Standard Treatment (Temozolomide With Concomitant Radiation Therapy, Followed by Temozolomide Maintenance Therapy) Versus Standard Treatment Alone (CENTRIC)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 17 May 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cilengitide (Primary) ; Temozolomide
  • Indications Glioblastoma
  • Focus Registrational; Therapeutic Use
  • Acronyms CENTRIC; EORTC-CENTRIC
  • Sponsors EMD Serono; Merck KGaA

    • Most Recent Events

    • 03 May 2024 Results (n=424) assessing treatment-associated imaging changes as per the modified response assessment in neuro-oncology (RANO) criteria of 2017 published in the Neuro-Oncology
    • 07 Jun 2022 Results of an analysis comparing survival outcome using patient-level data from clinical studies: NCT00943826, NCT00813943, NCT00689221 and real-world data from an institutional dataset at a large academic center presented at the 58th Annual Meeting of the American Society of Clinical Oncology
    • 19 Jan 2016 Pooled analysis of 4 studies (n=1869) including data from this study and 3 other trials (see CTP 700046838, 700038467, 700040257) were published in the Journal of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top